Universal Beteiligungs und Servicegesellschaft mbH Takes $109.83 Million Position in Pfizer Inc. (NYSE:PFE)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,139,926 shares of the biopharmaceutical company's stock, valued at approximately $109,832,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.07% of Pfizer as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Parsons Capital Management Inc. RI increased its position in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares during the period. Mcdonald Partners LLC grew its holdings in shares of Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after purchasing an additional 9,963 shares in the last quarter. Bank of Jackson Hole Trust acquired a new stake in shares of Pfizer during the 4th quarter worth $264,000. Harvey Capital Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth $544,000. Finally, ING Groep NV grew its holdings in shares of Pfizer by 48.6% during the 4th quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock worth $26,881,000 after purchasing an additional 331,403 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.3%

Shares of NYSE:PFE traded up $0.08 on Friday, hitting $23.53. 14,285,816 shares of the company's stock were exchanged, compared to its average volume of 41,001,758. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $133.75 billion, a PE ratio of 16.68, a P/E/G ratio of 0.64 and a beta of 0.58. The firm's 50-day moving average is $23.16 and its 200 day moving average is $25.09.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.31%. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PFE shares. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.